Cancer: markers, syndromes Flashcards
CA 15-3 (cancer antigen)
Breast cancer: 75% of metastatic disease
Bowel cancer
Lung cancer
(Cirrhosis, hepatitis, benign breast disease)
CA19-9 (Cancer antigen)
Pancreatic cancer Bowel cancer Lung cancer Gall bladder cancer (Gallstones, pancreatitis, cystic fibrosis, liver disease)
CEA (carcinoembryonic antigen)
Bowel cancer
Lung, Breast, Liver, Pancreas, Stomach, Ovary cancer
(IBD, liver disease)
SMRP (soluble mesothelin-related peptide)
Malignant mesothelioma
Thyroglobulin
Thyroid cancer: Used to assess completeness of removal of thyroid in throidectomy and recurrence of disease
AFP (alpha-fetoprotein)
Hepatocellular carcinoma
Germ-cell tumours (Testicular)
(Cirrhosis, chronic hepatitis)
BCGR (B-cell immunoglobulin gene rearrangement)
B-cell lymphoma
BCR-ABL
Chronic myeloid leukaemia (CML)
Acute lymphoblastic leukaemia (ALL)
CA-125 (cancer antigen)
Ovarian cancer: 80%
Endometrial cancer
Lung, breast, GI cancers
(Pregnancy, menstruation, endometriosis, PID)
Calcitonin
Medullary thyroid cancer (and precursor C-cell hyperplasia)
Lung, breast and pancreatic cancer, Insulinomas, leukaemia
CgA (chromogranin A)
Carcinoid tumours
Phaeochromocytoma
(Liver disease, IBD, renal disease)
Gastrin
Gastrinoma (hyperplasia of gastrin-producing cells)
hCG (human chorionic gonadothropin)
Gestational trophoblastic disease
Germ cell tumours (testis/ovaries)
Choriocarcinoma
HER-2 (Human epidermal growth factor receptor-2)
Tested on breast tumour cells
25-30% positive
Associated with faster growth
Targeted treatment (e.g. trastuzumab)
Oestrogen and progesterone receptors
Assessed on breast cancer tissue
Oestrogen and progesterone positive cancer is likely to respond to anti-hormone treatments (e.g. tamoxifen)